Wall Street Zen Upgrades Nuvectis Pharma (NASDAQ:NVCT) to "Hold"

Key Points

• Wall Street Zen upgraded Nuvectis Pharma from “sell” to “hold”, while Weiss Ratings reiterated a sell rating. Overall, MarketBeat shows the stock with a consensus Hold and a target price of $10.00.
• Nuvectis Pharma reported quarterly EPS of ($0.26), beating analyst expectations by $0.04. Analysts currently expect the company to post -$1.01 EPS for the full year.
• The stock recently traded at $11.65, near its 52-week high of $11.74, and above both its 50-day and 200-day moving averages. Institutional ownership remains very high, with 96.77% of shares held by institutions and hedge funds.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $10.00.

Nuvectis Pharma Stock Performance

NASDAQ NVCT opened at $11.65 on Friday. The firm has a market cap of $309.07 million, a PE ratio of -8.89 and a beta of -0.11. Nuvectis Pharma has a one year low of $5.55 and a one year high of $11.74. The firm's fifty day moving average is $8.56 and its two-hundred day moving average is $7.84.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Research analysts predict that Nuvectis Pharma will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NVCT. JPMorgan Chase & Co. increased its stake in shares of Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company's stock worth $47,000 after acquiring an additional 6,084 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Nuvectis Pharma during the second quarter worth about $53,000. Avalon Trust Co acquired a new position in shares of Nuvectis Pharma during the third quarter worth about $60,000. Bank of America Corp DE increased its stake in shares of Nuvectis Pharma by 417.2% during the second quarter. Bank of America Corp DE now owns 8,565 shares of the company's stock worth $64,000 after acquiring an additional 6,909 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Nuvectis Pharma by 3,671.4% during the fourth quarter. Deutsche Bank AG now owns 12,672 shares of the company's stock worth $96,000 after buying an additional 12,336 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.